Julian Ventres, PharmD BCPS
banner
juliambisome.bsky.social
Julian Ventres, PharmD BCPS
@juliambisome.bsky.social
Clinical pharmacist interested in infectious disease, antimicrobial resistance, and optimizing PK/PD targets

Also an avid birder and photographer
Reposted by Julian Ventres, PharmD BCPS
🆕🔥🔥CloCeBa RCT
Cloxacillin versus cefazolin for MSSA Bacteraemia
Cefazolin has a non-inferior efficacy regarding mortality, microbiological or clinical endpoints and was associated with a lower rate of serious adverse events #IDSky
www.thelancet.com/journals/lan...
October 19, 2025 at 4:34 AM
Reposted by Julian Ventres, PharmD BCPS
we're under-utilizing aminoglycosides for urosepsis in patients with good renal function

rising % ESBL is pushing us to use carbapenems for empiric therapy... leading to more resistance (CDiff, CRE)

aminoglycosides have minimal gut penetration = low CDiff risk & protect microbiome 🧵 #1/4 #EMIMCC
July 24, 2025 at 11:51 AM
Looking for people that have unrestricted linezolid at their institutions. Any increases in resistance? Better to just ease up on use criteria? Currently reviewing our own usage and seeing what we can do with rising tetracycline resistance in S. aureus #IDSky #AMSky
June 19, 2025 at 1:38 AM
Linezolid for odontogenic infections? Anyone doing this empirically? It feels like the data is there that LZD covers the relevant bugs, but there's no clinical data that I could find. Have to think LZD would be preferable to clinda #IDSky #AMSky
May 30, 2025 at 7:02 PM
Reposted by Julian Ventres, PharmD BCPS
Innoviva Specialty Therapeutics’ antibiotic is the first and only FDA-approved cephalosporin indicated to treat Staphylococcus aureus bacteremia, including right-sided endocarditis, caused by the methicillin-resistant Staphylococcus aureus. #IDsky #Medsky
Ceftobiprole Launches Commercially in US
Innoviva Specialty Therapeutics’ antibiotic is the first and only FDA-approved cephalosporin indicated to treat Staphylococcus aureus bacteremia (SAB), including right-sided endocarditis, caused by th...
www.contagionlive.com
May 20, 2025 at 2:57 PM
Reposted by Julian Ventres, PharmD BCPS
Derived from the PEN-FAST allergy decision tool, the CEPH-FAST version was developed and validated in this study. www.journalofinfection.com/article/S016...
  #IDsky #pharmsky
Development and Validation of a Cephalosporin Allergy Clinical Decision Rule
Utilising the previously published and internationally validated tool PEN-FAST, we validated the same criteria with minor modifications for low-risk cephalosporin allergies. The results suggest that a...
www.journalofinfection.com
May 5, 2025 at 12:39 PM
Reposted by Julian Ventres, PharmD BCPS
@steventong.bsky.social presents the results of the PSSA domain of the SNAP 🫰 trial - the worlds largest trial of staph aureus bacteremia - at #ESCMID2025

fluclox resulted in higher mortality and more AKI compared to penicillin for PSSA
April 12, 2025 at 2:45 PM
Reposted by Julian Ventres, PharmD BCPS
📝Here are my cliff notes for the recently FDA approved drug #gepotidacin #blujepa

www.idstewardship.com/drugs/gepoti...

🤔 Still wondering where the name comes from? It’s a yellow tablet… Kind of sounds like Jet Blue 🤷‍♂️

Anything to add? #IDsky
March 26, 2025 at 3:51 AM
If your institution has a Clinical Decision Unit for intermediate patients who may or may not need inpatient care, do they primarily use IV or PO antibiotics? Trying to push for more PO in this setting but also trying to anticipate challenges #IDSky #Pharmsky
March 8, 2025 at 3:22 PM
Reposted by Julian Ventres, PharmD BCPS
‼️The @idsainfo.bsky.social cUTI guideline 📄 draft is now available for public comment🗣️! This version has been reviewed by 15+ orgs & revised according to extensive feedback provided to us. www.idsociety.org/practice-gui...

UTIsky IDsky Medsky PharmSky
February 20, 2025 at 12:18 AM
Reposted by Julian Ventres, PharmD BCPS
An inpatient antimicrobial stewardship team driven penicillin allergy delabeling protocol for minimal and low-risk penicillin allergic patients #IDsky bit.ly/3EDPPOP
An inpatient antimicrobial stewardship team driven penicillin allergy delabeling protocol for minimal and low-risk penicillin allergic patients | Antimicrobial Stewardship & Healthcare Epidemiolog...
An inpatient antimicrobial stewardship team driven penicillin allergy delabeling protocol for minimal and low-risk penicillin allergic patients - Volume 5 Issue 1
bit.ly
February 17, 2025 at 5:39 PM
#IDSky preferred approach to recurrent MDR Pseudomonas? Respiratory isolate, currently on ceftazidime monotherapy.
Susceptible only to tobramycin. Avycaz, Zerbaxa and Recarbio sensis not done yet but previously resistant.
@bradspellberg.bsky.social @dralicehan.bsky.social @idiots-pod.bsky.social
February 10, 2025 at 10:31 PM
Reposted by Julian Ventres, PharmD BCPS
Breaking news🔥
US FDA approves EMBLAVEO (aztreonam and avibactam) for complicated intra-abdominal infections (cIAI) in adult patients who have limited or no alternative options #idsky
February 7, 2025 at 8:15 PM
Reading through some IV vs Oral endocarditis papers and loved this excerpt from Heldman 1996, "we felt that
we could not ethically require orally treated subjects to undergo the central venous catheter insertion and maintenance...only to deliver intravenous vehicle without active
drug" #IDSky
February 1, 2025 at 3:20 AM
Reposted by Julian Ventres, PharmD BCPS
All of human medicine rests on Streptomyces being kind of a dick neighbor
January 8, 2025 at 5:02 PM
Does your institution dose adjust micafungin for obesity? Clinical outcome data is lacking but what's there seems mixed overall, nothing really conclusive. I don't think I've ever used or seen 200mg daily personally

#IDSky #PharmSky
December 29, 2024 at 6:04 PM
As if 6 months wasn't good enough. Lenacapavir is already poised to be a game-changer in HIV PrEP, but once yearly?! I can't imagine how much this will improve access
Exciting news that Gilead will be testing a once-a-year injection of lenacapavir for HIV PrEP.

Again, its ability to reach its full potential, if found effective, will be in ensuring access, especially to those communities and countries most burdened by HIV.

www.statnews.com/2024/12/11/h...
Gilead to test once-a-year HIV prevention shot
Gilead is going to start testing a drug it believes could prevent HIV infection with just a single shot every year.
www.statnews.com
December 12, 2024 at 7:09 PM
How much is everyone using single dose aminoglycosides for cystitis? Just Enterobacterales? Or Pseudomonas as well? Good option to prevent admission for more resistant organisms? Always sucks admitting a stable patient solely due to resistance profile. #IDSky #PharmSky
December 12, 2024 at 2:02 PM
Reposted by Julian Ventres, PharmD BCPS
we updated our metronidazole dosing across UPMC system over a year ago based on Sunish's prelim work and now the final evaluation is published! so proud of him!! #idsky #amssky #pharmsky #medsky

www.sciencedirect.com/science/arti...
December 11, 2024 at 1:34 PM
Reposted by Julian Ventres, PharmD BCPS
On this day in 1981, a landmark paper in NEJM described four patients with evidence of immunodeficiency associated with PJP pneumonia, disseminated CMV, and Kaposi sarcoma. The disease would come to be known as HIV/AIDS. Revisit the paper: nej.md/41iekKD

#MedSky #IDSky
December 10, 2024 at 2:28 PM
#IDSky community, what are you/what do you see being used routinely for community SSTI? Are you still seeing SMX/TMP + cephalexin? Having trouble convincing my colleagues on SMX/TMP monotherapy when MRSA and Streptococcal coverage is wanted
December 5, 2024 at 3:01 PM
Reposted by Julian Ventres, PharmD BCPS
🆕 #Breakpoints Episode: Drs. @annegretemartson.bsky.social, Megan Wimmer, and Evan Clemens join me to discuss all things (Val)ganciclovir!!! #idsky #pharmsky #amssky @sidpharm.bsky.social

🎧 sidp.pinecast.co
November 29, 2024 at 3:47 PM
Reposted by Julian Ventres, PharmD BCPS
Endocarditis therapy has long been based on opinions of eminent experts rather than high-quality evidence
🔥PUBLISHED🔥
Our editorial with Dr.Spellberg✨️
@dremilymcd.bsky.social
@drtoddlee.bsky.social
Endocarditis Therapy: The Move From Expert Opinion to Evidence
www.sciencedirect.com/science/arti...
November 25, 2024 at 4:26 PM
Really shows that resistance isn't just about usage; mechanism and evolutionary/fitness costs play a huge part as well
#idsky
November 25, 2024 at 7:38 PM
Reposted by Julian Ventres, PharmD BCPS
Oral cephalosporins for pyelonephritis?!
🆕️⚡️⚡️COPY-ED
Multicenter, retrospective study
N=851
No difference in 14-day pyelonephritis treatment failure for oral cephalosporins* vs FQ/TMP-SMX for outpatient pyelonephritis in the ED #idsky #medsky
* Mostly cephalexin
www.sciencedirect.com/science/arti...
November 25, 2024 at 12:42 PM